MannkindLogoStackedPreferd.jpg
MannKind Corporation Participating at Upcoming Conferences
May 09, 2022 06:00 ET | MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannkindLogoStackedPreferd.jpg
MannKind Corporation Reports 2022 First Quarter Financial Results
May 05, 2022 16:00 ET | MannKind
1Q 2022 Afrezza Net Revenue of $9.8 million; +21% vs. 1Q 20211Q 2022 Afrezza Gross Margin 77%; Gross Profit +99% vs 1Q 2021$233.0 million of Cash, Cash Equivalents, and Investments at March 31,...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022
April 28, 2022 06:00 ET | MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host...
MannkindLogoStackedPreferd.jpg
MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30
April 27, 2022 06:05 ET | MannKind
Simplified 2x dose of Technosphere® Insulin (TI) produced a statistically significant improvement in PPGE between Dose 1 & 2 from 45-120 minutesHigher dose of TI resulted in a mean difference of...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference
March 28, 2022 06:05 ET | MannKind
DANBURY, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit
March 22, 2022 06:05 ET | MannKind
DANBURY, Conn., March 22, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference
March 08, 2022 06:05 ET | MannKind
DANBURY, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
MannkindLogoStackedPreferd.jpg
MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results
February 24, 2022 16:00 ET | MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 2021 Total Revenues of $75.4 million; +16% vs. 2020 4Q 2021 Afrezza Net Revenue of $11.3 million; +13% vs. 4Q 2020$260.7 million of Cash, Cash...
MannkindLogoStackedPreferd.jpg
Update on Tyvaso DPI™ New Drug Application
February 24, 2022 06:05 ET | MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022
February 21, 2022 09:05 ET | MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its...